
Oncology NEWS International
- Oncology NEWS International Vol 4 No 1
- Volume 4
- Issue 1
Rhône-Poulenc Forms Network To Develop Gene and Cell Therapies
COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc. (Paris, France) has formed a new division, RPR Gencell, dedicated to the discovery, development, and commercialization of cell and gene therapy products. To accelerate such discoveries, the company has also created a biotechnology network comprising 14 biotech companies and academic research centers.
COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc. (Paris, France)has formed a new division, RPR Gencell, dedicated to the discovery,development, and commercialization of cell and gene therapy products.To accelerate such discoveries, the company has also created abiotechnology network comprising 14 biotech companies and academicresearch centers.
The US members of the collaboration are Genetix Pharmaceuticals(New York City), The Lawrence Berkeley Laboratory Human GenomeCenter (Berkeley, Calif), Applied Immune Sciences, Inc. (SantaClara, Calif), Darwin Molecular Corporation (Seattle), and IntrogenTherapeutics, Inc. (Houston).
The other network members are French, including the Centre Nationalde Recherche Scientifique (CNRS), the Institut Gustave Roussy,and the Université Louis Pasteur.
Articles in this issue
over 31 years ago
MDs Fear Managed Care Equals Lower-Quality Careover 31 years ago
Dallas Medical Center Launches Umbilical Stem Cell Projectover 31 years ago
Ethyol Approved for Use in the UKover 31 years ago
Assessment Tools Are Essential to Improve Management of Painover 31 years ago
Undertreating Pain Costs Money in the Long Run, Physician Warnsover 31 years ago
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCIover 31 years ago
EORTC Endometrial Ca Trial Challenges Findings From GOGNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content


138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer

















































